Matteo Boattini

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Gabriele Bianco

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

Cristina Costa

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

Rossana Cavallo

University of Turin

Sara Comini

University of Turin

Marco Iannaccone

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

André Almeida

Universidade do Estado de Minas Gerais

Roberto Casale

University of Turin

Paolo Gaibani

University of Verona

Valentina Tosatto

Hospital de Santa Marta

Alessandro Bondi

University of Turin

Cooperative Institutions

University of Turin

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

Centro Hospitalar de Lisboa Central

Hospital de Santa Marta

Universidade Nova de Lisboa

University of Bologna

Istituti di Ricovero e Cura a Carattere Scientifico

Fondazione Ricerca Molinette

Policlinico S.Orsola-Malpighi

Piedmont Reference Center for Epidemiology and Cancer Prevention

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

In vivo emergence of ceftazidime/avibactam, cefiderocol and aztreonam/avibactam cross-resistance in a patient with KPC-producing Klebsiella pneumoniae infection after Cefiderocol-based treatment

International Journal of Antimicrobial Agents (2024)

Gabriele Bianco Matteo Boattini Sara Comini Davide Gibellini Paolo Gaibani

Ceftazidime/avibactam

Aztreonam

Avibactam

10.1016/j.ijantimicag.2024.107343

Cite

Citations (2)

From Forgotten Pathogen to Target for New Vaccines: What Clinicians Need to Know about Respiratory Syncytial Virus Infection in Older Adults

Viruses (2024)

Matteo Boattini André Almeida Sara Comini Gabriele Bianco Rossana Cavallo

Respiratory syncytial virus (RSV) is increasingly recognized as being implicated in acute illness in older adults, with a significant weight in hospitalizations for respiratory illness and death. By means of a best-evidence review, this paper aims to investigate whether RSV can be considered a forgotten pathogen in older patients, looking at trends in the literature volume and exploring possible epidemiological and clinical features underlying the focus given to it. We then present an assessment of its disease burden and present and future strategies for its reduction, particularly in light of the recent availability of new vaccines.

Respiratory illness

10.3390/v16040531

Cite

Citations (7)

Auditory agnosia in a patient with nephrotic syndrome

BMJ Case Reports (2013)

Matteo Boattini Giorgia Arnone Gaetano Procaccianti

A 70-year-old woman with nephrotic syndrome (NS) secondary to membranous glomerulonephritis on immunosuppressive therapy, diabetic nephropathy and hypertension presented with sudden hearing impairment. She had lost the ability to understand speech and transiently expressed some meaningless words. Reading and writing skills were preserved, and she was able to understand written commands. Audiometry revealed mild bilateral sensorineural hearing loss. Brain MRI showed a recent left temporal ischaemic lesion (figure 1; white arrow) and right temporal, left occipital and …

Agnosia

10.1136/bcr-2012-008164

Cite

Citations (2)

Shock following subcutaneous injections of polymethylmethacrylate

Medicina Intensiva (English Edition) (2015)

Matteo Boattini A.R. Francisco Raquel Cavaco João V. Rodrigues Luís Bento

10.1016/j.medine.2015.04.001

Cite

Citations (0)

Left Hemibody Swelling in an HIV-Positive Patient with Congenital Heart Disease

Case Reports in Vascular Medicine (2012)

Matteo Boattini André Almeida Rita Barata Moura Miguel Toscano Rico

We report the case of a 50-year-old HIV-positive woman with a congenital cyanotic heart disease who developed left axillary, subclavian, and brachiocephalic vein thrombosis and left lower aortopulmonary collateral arterial thrombosis, presenting as left hemibody swelling. We also briefly overview the literature regarding upper extremity deep vein thrombosis (UEDVT). Given the absence of other risk factors, it was our firm believe that our patient's UEDVT was due to a hypercoagulable state associated with congestive heart failure (CHF) and HIV infection.

10.1155/2012/569095

Cite

Citations (0)

Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018–2022)

European Journal of Clinical Microbiology & Infectious Diseases (2023)

Matteo Boattini Gabriele Bianco Paulo Bastos Sara Comini Silvia Corcione

Abstract Introduction Ceftazidime/avibactam-resistance in Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) is a topic of great interest for epidemiological, diagnostic, and therapeutical reasons. However, data on its prevalence and burden on mortality in patients with bloodstream infection (BSI) are lacking. This study was aimed at identifying risk factors for mortality in patients suffering from ceftazidime/avibactam-resistant KPC-Kp BSI. Methods An observational retrospective study (January 2018–December 2022) was conducted at a tertiary hospital including all consecutive hospitalized adult patients with a ceftazidime/avibactam-resistant KPC-Kp BSI. Data on baseline clinical features, management, and admission outcomes were analyzed. Results Over the study period, among all the KPC-Kp BSI events recorded, 38 (10.5%) were caused by ceftazidime/avibactam-resistant KPC-Kp strains, 37 events being finally included. The ceftazidime/avibactam-resistant KPC-Kp strains revealed susceptibility restoration to at least one carbapenem in more than 60% of cases. In-hospital and 30-day all-cause mortality rates were 22% and 16.2%, respectively. Non-survivors suffered from more baseline comorbidities and experienced a more severe ceftazidime/avibactam-resistant KPC-Kp BSI presentation (i.e., both the Pitt Bacteremia and INCREMENT-CPE scores were significantly higher). Presenting with a higher Charlson Comorbidity Index, chronic kidney disease—KDIGO stage 3A or worse—having recently gone through renal replacement therapy, having suffered from an acute kidney injury following the ceftazidime/avibactam-resistant KPC-Kp BSI, and being admitted for cardiac surgery were the strongest predictors of mortality. Conclusion Ceftazidime/avibactam resistance in KPC-Kp BSI easily emerged in our highly KPC-Kp endemic area with remarkable mortality rates. Our findings might provide physicians possibly actionable information when managing patients with a ceftazidime/avibactam-resistant KPC-Kp BSI.

Ceftazidime/avibactam

Avibactam

Bacteremia

10.1007/s10096-023-04712-8

Cite

Citations (9)

Direct detection of extended-spectrum-β-lactamase-producers in Enterobacterales from blood cultures: a comparative analysis

European Journal of Clinical Microbiology & Infectious Diseases (2021)

Matteo Boattini Gabriele Bianco Sara Comini Marco Iannaccone Roberto Casale

Medical microbiology

Blood Culture

10.1007/s10096-021-04385-1

Cite

Citations (13)

In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam: an Italian nationwide multicentre observational study (2022–23)

Journal of Antimicrobial Chemotherapy (2024)

Gabriele Bianco Matteo Boattini Laura Isabella Lupo Simone Ambretti Rita Greco

To evaluate the in vitro activity of ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae (KPC-Kp) clinical isolates collected from a multicentre study in Italy (2022-23) and genomic characterization of the molecular mechanisms causing resistance. Consecutive KPC-Kp isolates from blood cultures (n = 264) were collected from 14 hospital centres in the period 2022-23. Antimicrobial susceptibility testing was performed using broth microdilution. WGS was used to investigate KPC-Kp strains resistant to the new approved β-lactam/β-lactam inhibitor combinations (BLICs). Overall, meropenem/vaborbactam (95.1% susceptible by EUCAST and 93.9% susceptible by CLSI; MIC50 = 0.5 mg/L; MIC90 = 4 mg/L) and imipenem/relebactam (97% susceptible by EUCAST and 92.8% susceptible by CLSI; MIC50 = 0.25 mg/L; MIC90 = 0.5 mg/L) showed similar activity, followed by ceftazidime/avibactam (93.9% susceptible by both EUCAST and CLSI; MIC50 = 2 mg/L; MIC90 = 8 mg/L). Ten out of 13 (76.9%) KPC-Kp resistant to ceftazidime/avibactam carried a blaKPC variant including blaKPC-31, blaKPC-205, blaKPC-203 and blaKPC-93. Among KPC-Kp resistant to meropenem/vaborbactam and imipenem/relebactam, 90.9% (10/11) and 80% (4/5) harboured a WT carbapenemase (i.e. blaKPC-2 or blaKPC-3), respectively. All strains resistant to meropenem/vaborbactam and/or imipenem/relebactam carried truncated OmpK35 and/or mutated (ins135GD) OmpK36. New BLICs were shown to be the most widely active therapeutic option against KPC-Kp clinical isolates collected in Italy. Ceftazidime/avibactam resistance is mainly driven by the expression of KPC variants, whereas the loss of function of the OmpK35 and OmpK36 porins appears to play a key but not exclusive role in the development of meropenem/vaborbactam and/or imipenem/relebactam resistance.

Ceftazidime/avibactam

Avibactam

Blood Culture

10.1093/jac/dkae450

Cite

Citations (0)

Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era

European Journal of Clinical Microbiology & Infectious Diseases (2022)

Gabriele Bianco Matteo Boattini Sara Comini Roberto Casale Marco Iannaccone

Ceftazidime/avibactam

Aztreonam

Broth microdilution

Avibactam

10.1007/s10096-022-04408-5

Cite

Citations (37)

Multicentre Evaluation of the EUCAST Rapid Antimicrobial Susceptibility Testing (RAST) Extending Analysis to 16–20 Hours Reading Time

Antibiotics (2022)

Gabriele Bianco Donatella Lombardo Guido Ricciardelli Matteo Boattini Sara Comini

The aim of the study was to evaluate the EUCAST RAST method by extending analysis to 16–20 h reading time and performance with new β-lactam/β-lactamase inhibitor combinations. A total of 676 positive blood cultures (BCs) were enrolled. Results at 4 h, 6 h, 8 h and 16–20 h were interpreted according to bacterial species using EUCAST RAST breakpoints (version 5.1). For species for which no breakpoints were available, tentative breakpoints were used. Categorical agreement with the Microscan microdilution system was analysed. Among the 676 BCs enrolled, 641 were monomicrobial and were included in the analysis. Categorical agreement ranged from 98.9% at 4 h to 99.4% at 16–20 h. The rates of very major errors were 3.3%, 3.7% and 3.4% at 4 h, 6 h and 8 h, respectively, and decreased to 1% at 16–20 h (p < 0.001). The number of major errors was low for each reading time (0.2% and 0.4% at 4 h and 6 h, respectively, and 0.3% at both 8 h and 16–20 h). The proportions of results in the area of technical uncertainty were 9.9%, 5.9%, 5% and 5.2% for readings at 4 h, 6 h, 8 h and 16–20 h, respectively. Tentative breakpoints proposed for Enterobacterales other than E.coli/K.pneumoniae and coagulase-negative staphylococci showed overall performances comparable to those observed for E. coli/K. pneumoniae and S. aureus. In conclusion, EUCAST RAST has been shown to be reliable to determine microbial susceptibility to main antimicrobials, including ceftazidime/avibactam and ceftolozane/tazobactam. A poorer performance was observed for certain species/antimicrobial agent combinations. The better performance observed at 16–20 h compared to the early readings may confer to the method greater potential for antimicrobial de-escalation interventions.

Broth microdilution

10.3390/antibiotics11101404

Cite

Citations (9)